Novo Nordisk A/S : Novo Nordisk A/S - aktietilbagekøbsprogram

February 27, 2012 08:07 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

Den 2. februar 2012 iværksatte Novo Nordisk et aktietilbagekøbsprogram i henhold til bestemmelserne i Europa-Kommissionens forordning nr. 2273/2003 af 22. december 2003, også kaldet 'Safe Harbour'-reglerne.

Attachments

Selskabsmeddelelse nr 14 2012...

Recommended Reading

October 02, 2026 16:53 ET | Source: Novo Nordisk A/S

Novo provides update on the denecimig Biologics License Application (BLA) in the US

The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for...
Read More
October 01, 2026 06:45 ET | Source: Novo Nordisk A/S

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat
Read More